Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professors Stephanie Dakin and Paul Bowness have been announced as 2021 recipients of the Novartis Institutes for BioMedical Research (NIBR) Global Scholars Program (NGSP).

Professors Steph Dakin and Paul Bowness

NGSP is a competitive program designed for innovators from invited institutions to gain funding for breakthrough science that will advance Novartis' mission to improve and extend peoples' lives.

Stephanie Dakin, Associate Professor of Musculoskeletal Sciences at NDORMS joined NGSP to further her research into tendinopathy. She said: "I am delighted and honoured to be recognised as a recipient of the NIBR Global Scholars Program and look forward to establishing a fruitful collaboration with Novartis. This strong collaborative link between academia and pharma provides a unique opportunity to catalyse the development of new therapeutic strategies for tendinopathy treatment."

Paul Bowness, Professor of Experimental Rheumatology will be using his time on the NGSP to focus on finding new ways to understand and treat Spondyloarthritis. "I am excited and honoured to be one of the recipients of 2021 NIBR Global Scholars Program," said Paul. "In collaboration both with Dr Liye Chen at NDORMS and the team at Novartis, we will investigate the scientific mechanisms and therapeutic potential of novel approaches in Spondyloarthritis, a common group of arthritic diseases affecting young people all over the world."

Stephanie and Paul were among five recipients of the program in 2021 and, together with Novartis, they will explore new scientific frontiers in drug discovery and/or clinical research to improve the lives of patients.